Latest News & Insights
Stay Up to Date with Our Community
Featured
October 16, 2024
Latigo Biotherapeutics, Inc. (“Latigo”) today announced that the first participant has been dosed in its Phase 1 clinical trial of...
Loading...
October 16, 2024
Latigo Biotherapeutics, Inc. (“Latigo”) today announced that the first participant has...
October 16, 2024
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on...
October 7, 2024
CAP-003 achieved best-in-class GCase increases in NHPs exceeding levels needed for...
September 16, 2024
Warner Biddle Appointed as Chief Executive Officer and to Board of...
September 9, 2024
In a recent article in Endpoints, Astellas highlights its work in...
September 9, 2024
Latigo Biotherapeutics Inc. ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid...
September 4, 2024
Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company...
July 22, 2024
Latigo Biotherapeutics Inc. (“Latigo”), a clinical-stage biotechnology company developing best-in-class non-opioid...
June 26, 2024
Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class...